A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

As the battle against obesity and diabetes heats up, two new superstars are entering the ring in Spain - Mounjaro (also known ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

but it’s “particularly problematic” for GLP-1 drugs—such as semaglutide (Ozempic, Wegovy, and Rybelsus; Novo Nordisk) and ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide ... year – once-weekly injections of tirzepatide at three dose levels – 5, 10, and 15 mg – achieved a 94% reduction ...

Mounjaro was approved by the Food and Drug Administration (FDA) in May and, while not rising to the level of game-changer, it’s a first-of-its-kind dual ... dose of 5 mg, 10 mg, or 15 mg, or ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Understanding the right dose of Ozempic for you can feel a bit confusing, especially if you’re just getting started. While ...

Ozempic, a drug initially intended for type 2 diabetes treatment, is gaining popularity for weight loss and reducing cardiovascular risks. However, researchers caution about potential side effects ...